Indomethacin increases severity of Clostridium difficile infection in mouse model

  • Juan Muñoz-Miralles
  • , Bruno C. Trindade
  • , Pablo Castro-Córdova
  • , Ingrid L. Bergin
  • , Leslie A. Kirk
  • , Fernando Gil
  • , David M. Aronoff*
  • , Daniel Paredes-Sabja
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Aim: To evaluate the effect on the nonsteroidal anti-inflammatory drug indomethacin on Clostridium difficile infection (CDI) severity. Materials & methods: Indomethacin was administered in two different mouse models of antibiotic-associated CDI in two different facilities, using a low and high dose of indomethacin. Results: Indomethacin administration caused weight loss, increased the signs of severe infection and worsened histopathological damage, leading to 100% mortality during CDI. Indomethacin-treated, antibiotic-exposed mice infected with C. difficile had enhanced intestinal inflammation with increased expression of KC, IL-1β and IL-22 compared with infected mice unexposed to indomethacin. Conclusion: These results demonstrate a negative impact of nonsteroidal anti-inflammatory drugs on antibiotic-associated CDI in mice and suggest that targeting the synthesis or signaling of prostaglandins might be an approach to ameliorating the severity of CDI.

Original languageEnglish
Pages (from-to)1271-1281
Number of pages11
JournalFuture Microbiology
Volume13
Issue number11
DOIs
StatePublished - Sep 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2018 Future Medicine Ltd.

Keywords

  • Prostaglandins

Fingerprint

Dive into the research topics of 'Indomethacin increases severity of Clostridium difficile infection in mouse model'. Together they form a unique fingerprint.

Cite this